EZH2 and breast cancer: Mechanistically, inhibition of EZH2 histone methyltransferase activity alone by EZH2 inhibitors in BC cells could reduce the enrichment of H3K27me3 on the CCL2 gene promoter and increase CCL2 transcription and CCL2 protein secretion, contributing to the induction of M2 polarization and recruitment of TAMs in TMEs.